3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Winston Wright of Alto, Serafina Lalany of Houston Exponential, and Zeev Braude of SiteAware. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from startup development to construction technology — recently making headlines in Houston innovation.

Winston Wright, Houston general manager at Alto

Winston Wright leads Houston operations for Dallas-based Alto, which is taking on the likes of Uber and Lyft. Photo courtesy of Alto

As any Houstonian knows, the city is quite large. While Dallas-based Alto, a luxury rideshare service, rolled out in Houston a while ago, Winston Wright has plans to make sure the company is covering the entire greater Houston area.

Wright, who's the Houston general manager for Alto, joined last week's episode of the Houston Innovators Podcast. He shares more on Alto's future in Texas and beyond, as well as what's challenging him most as he grows the team locally.

"The vision I have for this market is that, as we move forward and continue to expand, that we're covering all of Houston," he says. Click here to read more and to listen to the episode.

Serafina Lalany, executive director of Houston Exponential

Houston Exponential appoints new executive director and restructures its boardHX has its new permanent leader. Photo courtesy of Serafina Lalany

It's a new era for Houston Exponential, and Serafina Lalany, named the organization's executive director last September, is leading HX into its new phase.

"The interesting thing of being an organization of ex-startup operators is that we operate as a startup ourselves," she tells InnovationMap. "Along the journey of supporting and building infrastructure for a startup community, we have also been seeking our own product market fit. I think we're at the place now where we have a profound realization of what that is and who we serve. We have crystal clear vision around that."

Lalany discusses more of her plans for HX for 2022 and shares how the organization is evolving to be what Houston's innovation ecosystem needs in an interview. Click here to read more.

Zeev Braude, CEO of SiteAware

Houston-based SiteAware has raised $15 million in its latest round of funding. Photo courtesy of SiteAware

SiteAware, a Houston construction software startup, raised $15 million in its series B round, which was led by Singapore-based Vertex Ventures Israel. Existing investors Robert Bosch Venture Capital GmbH, Axon Ventures, Oryzn Capital, The Flying Object, and lool Ventures also contributed to the round.

The company's digital construction verification, or DCV, platform uses AI and digital twin technology to provide real-time verification of construction fieldwork. According to a press release from SiteAware, the construction industry represents a $1.3 trillion market share of the United States economy.

"SiteAware's DCV error prevention technology is disrupting the construction industry by dramatically accelerating schedules and streamlining work processes for all parties. In the next few years, everyone from contractors to developers will be using DCV to build without rework," says Zeev Braude, CEO of SiteAware, in a news release. "DCV gives the construction ecosystem access to data they've never had before, data that holds the key to the next jump in productivity for the industry." Click here to read more.

Winston Wright leads Houston operations for Dallas-based Alto, which is taking on the likes of Uber and Lyft. Photo courtesy of Alto

Dallas-based ridesharing app gears up for expansion across Houston and beyond

HOUSTON INNOVATOR PODCAST EPISODE 118

Before he started his current job, Winston Wright would have thought a startup attempting to compete with the likes of Uber and Lyft was going to fight an uphill battle. Now, he sees how much opportunity there is in the rideshare market.

Wright is the Houston general manager for Alto, a Dallas-based company that's grown its driving service platform into five markets — first from Dallas into Houston and then to Los Angeles, Miami, and, most recently, Washington D.C. Alto's whole goal is to provide reliability and improve user experience.

"We're elevating ridesharing," Wright says on this week's episode of the Houston Innovators Podcast. "With Alto, you get a consistent, safe experience with. a high level of hospitality. And that's a key differentiator for us in the market, and we're able to replicate that time and time again."

Wright, whose background is in sales and operations in hospitality, says his vision for alto in Houston is to expand the service — which operates in the central and western parts of the city — throughout the greater Houston area.

"The vision I have for this market is that, as we move forward and continue to expand, that we're covering all of Houston," he says.

This will mean expanding the company's physical presence too. Alto recently announced its larger space in Dallas, and now the Houston operations facility will grow its footprint too.

Wright says he's also focused on growing his team. Over the past two years, pandemic notwithstanding, the company has maintained hiring growth. Alto's drivers are hired as actual employees, not contractors, so they have access to benefits and paid time off.

The company, which raised $45 million in its last round of investment, is expanding next to the Silicon Valley area, followed by three to five more markets in 2022. Then, by the end of 2023, it's Alto's mission to have a completely electronic fleet of vehicles.

"Our goal is to have over 3,000 EV cars and be the first company with a 100 percent electric fleet by 2023," Wright says.

Wright shares more on Alto's future in Texas and beyond, as well as what's challenging him most as he grows the team locally. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Rice team keeps CO2-to-fuel devices running 50 times longer in new study

Bubbling Up

In a new study published in the journal Science, a team of Rice University researchers shared findings on how acid bubbles can improve the stability of electrochemical devices that convert carbon dioxide into useful fuels and chemicals.

The team led by Rice associate professor Hoatian Wang addressed an issue in the performance and stability of CO2 reduction systems. The gas flow channels in the systems often clog due to salt buildup, reducing efficiency and causing the devices to fail prematurely after about 80 hours of operation.

“Salt precipitation blocks CO2 transport and floods the gas diffusion electrode, which leads to performance failure,” Wang said in a news release. “This typically happens within a few hundred hours, which is far from commercial viability.”

By using an acid-humidified CO2 technique, the team was able to extend the operational life of a CO2 reduction system more than 50-fold, demonstrating more than 4,500 hours of stable operation in a scaled-up reactor.

The Rice team made a simple swap with a significant impact. Instead of using water to humidify the CO2 gas input into the reactor, the team bubbled the gas through an acid solution such as hydrochloric, formic or acetic acid. This process made more soluble salt formations that did not crystallize or block the channels.

The process has major implications for an emerging green technology known as electrochemical CO2 reduction, or CO2RR, that transforms climate-warming CO2 into products like carbon monoxide, ethylene, or alcohols. The products can be further refined into fuels or feedstocks.

“Using the traditional method of water-humidified CO2 could lead to salt formation in the cathode gas flow channels,” Shaoyun Hao, postdoctoral research associate in chemical and biomolecular engineering at Rice and co-first author, explained in the news release. “We hypothesized — and confirmed — that acid vapor could dissolve the salt and convert the low solubility KHCO3 into salt with higher solubility, thus shifting the solubility balance just enough to avoid clogging without affecting catalyst performance.”

The Rice team believes the work can lead to more scalable CO2 electrolyzers, which is vital if the technology is to be deployed at industrial scales as part of carbon capture and utilization strategies. Since the approach itself is relatively simple, it could lead to a more cost-effective and efficient solution. It also worked well with multiple catalyst types, including zinc oxide, copper oxide and bismuth oxide, which are allo used to target different CO2RR products.

“Our method addresses a long-standing obstacle with a low-cost, easily implementable solution,” Ahmad Elgazzar, co-first author and graduate student in chemical and biomolecular engineering at Rice, added in the release. “It’s a step toward making carbon utilization technologies more commercially viable and more sustainable.”

A team led by Wang and in collaboration with researchers from the University of Houston also recently shared findings on salt precipitation buildup and CO2RR in a recent edition of the journal Nature Energy.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings